Regeneron Pharmaceuticals
Develops biopharmaceutical therapies for serious diseases
Field Reimbursement Manager - Neurology
More locations: Manchester, NH, USA | Cleveland, OH, USA | Pittsburgh, PA, USA | Albany, NY, USA | Columbus, OH, USA | Buffalo, NY, USA | New Haven, CT, USA
Field-based role; on-site expectations may apply depending on the location.
About the job
- A bachelor's degree and at least 5 years of experience in biopharma reimbursement, market access, or field-based access roles working in a matrix environment, including at least 2 years of direct reimbursement experience supporting medical benefit therapies; buy-and-bill experience is preferred.
- Experience across buy-and-bill and specialty pharmacy distribution models, including white bagging and site-of-care management.
- Develop and execute account-specific access and reimbursement plans that support product launch, optimize site of care based on payer policy and patient needs, build reimbursement confidence with customers, and support continued patient access.
- Educate accounts on patient support services and collaborate with Patient Services to support patient onboarding, therapy initiation, and ongoing treatment.
- Develop collaborative relationships with Sales, Patient Services, Account Directors, and Medical to align access strategy and remove barriers to therapy initiation.
- Partner cross-functionally to ensure consistent and accurate Risk Evaluation and Mitigation Strategies communication and field execution.
- Coordinate between provider offices, specialty pharmacies, and infusion sites.
- Guide healthcare professionals in resolving access challenges, including prior authorizations, denials, appeals, and payer site-of-care restrictions, in accordance with company policies and processes.
- Anticipate and adapt to evolving launch dynamics, payer policies, and distribution pathway changes.
- Plan and manage efficient and effective coverage of the assigned field reimbursement territory.
- Establish relationships with access champions, including providers, administrators, office staff, and financial coordinators, to support access readiness and ongoing therapy delivery.
- Update customers on payer policy evolution, coding updates such as J-code progression, and site-of-care management trends.
- Rare disease experience.
- Experience supporting product launches.
About the company
Regeneron Pharmaceuticals develops and commercializes medicines for serious diseases, with a focus on cancer, eye diseases, allergic and inflammatory diseases, and infectious diseases. Its products come from using proprietary research capabilities and technologies to discover and develop therapies, often in collaboration with academic, research, and industry partners. Revenue comes from selling approved medicines and from licensing its technologies and entering co-development and co-commercialization partnerships. The company works with healthcare providers and regulators to ensure treatment delivery and safety. Its goal is to improve patient outcomes by bringing life-transforming medicines to market through rigorous R&D and strategic collaborations, maintaining leadership in biopharmaceutical innovation.
Company Size
10,001+
Company Stage
IPO
Headquarters
Town of Mount Pleasant, New York
Founded
1988
Get referred to Regeneron Pharmaceuticals
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 revenue rose 17% to $4.3 billion, driven by Dupixent and Eylea HD.
- Dupixent global sales hit $6.0 billion, while Libtayo and Eylea HD hit records.
- The Sanofi Development Balance was fully repaid, boosting future collaboration revenue starting Q3 2026.
What critics are saying
- May 2026's failed fianlimab melanoma trial sparked an $11 billion market-cap wipeout.
- The August 2026 securities class action targets Regeneron's trial disclosures through May 15, 2026.
- Eylea faces transition pressure as patients shift to Eylea HD and competing anti-VEGF drugs.
What makes Regeneron Pharmaceuticals unique
- Regeneron's antibody platforms keep producing approved drugs like Dupixent, Eylea HD, and Libtayo.
- The April 2026 Telix collaboration extends its oncology platform into radiopharmaceuticals.
- Cemdisiran's November 2026 FDA decision gives Regeneron a near-term, differentiated complement catalyst.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Wellness Program
Paid Vacation
Equity Awards
Annual Bonuses
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 10%1 year growth
↑ 12%2 year growth
↑ 12%Regeneron Pharmaceuticals' stock has declined roughly 1% this year, despite being a strong long-term performer. The biotech company will report third-quarter earnings on 30 October, which could provide a catalyst for the struggling share price. When Regeneron last reported results in July, revenue totalled $4.3 billion, up 17% year-over-year. Global sales of Dupixent and Libtayo rose 38% and 30% respectively, whilst Eylea HD revenue in the US climbed 52%. The strong figures pushed the stock to a new 52-week high in early September. The company has roughly 50 product candidates in development. Regeneron trades at 19 times trailing earnings and less than 15 times forward earnings, compared to the S&P 500's multiples of 23 and 20 respectively.
Regeneron Pharmaceuticals, Inc. (REGN) presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum transcript. 162.3K Followers Regeneron Pharmaceuticals, Inc. (REGN) Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum September 23, 2026 10:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis Christopher Fenimore - Executive VP of Finance & CFO Conference Call Participants Jeffrey Walch - Bernstein Institutional Services LLC, Research Division Presentation Jeffrey Walch Bernstein Institutional Services LLC, Research Division Thank you so much for our next conversation with health care leaders and disruptors. I have the pleasure of speaking with Regeneron Pharmaceuticals. My name is Jeffrey Walch. I'm one of the analysts at Bernstein, I cover U.S. Biotechnology. And I'm very excited today to talk to 2 of the senior leaders at Regeneron, Chris Fenimore, EVP, Finance and CFO; and Ryan Crowe, SVP, Investor Relations. Before we kick off, I think, Ryan, you have something to read. Ryan Crowe Senior Vice President of Investor Relations & Strategic Analysis I sure do, Jeffrey. Thank you so much for having us. And I'll just briefly read a forward-looking statement reminder that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found in Regeneron's SEC filings. Regeneron does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. And with that, Jeffrey, why don't we hop into your questions? Question-and-Answer Session Jeffrey Walch Bernstein Institutional Services LLC, Research Division Perfect. Well, thank you once again, both of you for chatting with us today. I'll sort of ask the question and whoever or both of you that would like to answer, feel free to do so. So first off, congrats on
Novo Nordisk and Regeneron Pharmaceuticals represent distinct pharmaceutical investment opportunities. Novo Nordisk specialises in metabolic disorders, particularly diabetes and obesity treatments, serving patients in roughly 170 countries with a workforce of about 68,800. In fiscal 2025, Novo Nordisk generated nearly $47.7 billion in revenue, up 6.4% year-over-year, with net income of approximately $15.8 billion. The company's net margin stood at 33.1%, whilst its debt-to-equity ratio was 0.7x. Free cash flow reached nearly $4.5 billion. Regeneron focuses on treatments for eye diseases, cancer, and inflammatory conditions using proprietary technologies. The company maintains strategic partnerships with Sanofi and Bayer. In July 2026, Regeneron expanded its cancer therapy pipeline through collaboration with Telix Pharmaceuticals. Notably, two distributors accounted for roughly 77% of Regeneron's gross product revenue in 2025, creating customer concentration risk.
Supply Chain Digital's Transformation Project of the Year. September 14, 2026 Following on from the Global Supply Chain Awards, Supply Chain Digital take a look at the organisation recognised for the Transformation Project of the Year Award The Global Supply Chain Awards 2026 recognised companies who are going above and beyond, demonstrating excellence in a time of complexity. Leaders from around the world gathered on the 8 September, to see who won across the Global Supply Chain Awards, co-located with the Global Procurement Awards and the Global Sustainability Awards. Regeneron Pharmaceuticals gained recognition for its 'Speed to Science' project, earning the gold medal for the Transformation Project of the Year Award. Transformation Project of the Year. Supply chains have undergone significant changes in recent years, driven by ongoing volatility and the emergence of technology. The Transformation Project of the Year award acted as an opportunity to celebrate the organisations which have delivered successful transformation projects. It looked at those which have shown to improve efficiency, agility and performance through redesign, digitalisation or innovation. The nominees were: * Creating A Stronger, Smarter Global Supply Chain - East West Manufacturing * ATCO's Momentous, Really-Big-Deal Procurement Transformation - ProcureAbility - Jabil * Flow State: Turning Supply Fragility into Predictable Flow - Seqwater (Silver) * Transforming Healthcare Access: Building Integrated Digital Healthcare Ecosystem - Unitel LLC (Bronze) Regeneron Pharmaceuticals won the first place award with its project, Speed to Science: Transforming the Lab Supplies Category, Regeneron Pharmaceuticals. Regeneron in the lead. Every day, people are searching for answers to their illnesses, facing uncertainties about their health, their diagnosis and their treatments. Regeneron Pharmaceuticals aims to end this uncertainty, helping speed up the process of treatment without sacrificing quality. At Regeneron, teams of scientists, researchers and more are looking to deepen their understandings in order to advance research and unlock new innovations in healthcare. This project focused on rebuilding the company's lab supplies programme across three global sites in order to get the right products that allowed scientists to focus on their discoveries. Through this project, Regeneron achieved 85% adoption in year one, saving more than 750 administrative hours. This is a demonstration of the work Regeneron's team have been putting in in order to create a wider impact - by getting the right technology and the most effective products, teams have seen greater efficiency across one of the most critical supply chains. Winner insights. Upon receipt of this award, Supply Chain Digital spoke to Deborah Waterhouse, Associate Director at Regeneron. How does it feel to win this award? It feels great. Supply Chain Digital has worked hard as a team, not just who are here tonight, but also the team that Supply Chain Digital support. It's its stakeholders and its procurement leads and everybody else that supports the team. Could you tell me about the project and why you won this award? It was a lot of hard work. Supply Chain Digital has done a lot over the last 18 months of really focusing on what Supply Chain Digital needed to change within its supply chain and ensuring that Supply Chain Digital could move forward with transforming through sustainability solutions, through a value that Supply Chain Digital can deliver to the organisation. So delivering in so many opportunities and value beyond savings. How can supply chain leaders adapt to current world events? There's so much that Supply Chain Digital need to focus on. I think AI is going to play a big role in that as well, about how Supply Chain Digital use data and analytics to really support its organisations in the future. So it's very exciting to see how Supply Chain Digital can also adapt to that and really consider what is really, truly important going forwards. Finally, what does the future look like for your project? There's still a lot of work to be done. It never ends. So transformation means transformation. It requires a lot of change, people being on board for that and looking at what the next step is in its innovation and how Supply Chain Digital perform going forwards. Company Portals
Regeneron Pharmaceuticals' EYLEA franchise generated approximately $5.97 billion in US sales during 2024, according to a new market analysis report covering major pharmaceutical markets through 2034. The ophthalmology treatment addresses serious retinal diseases including neovascular age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. Standard-dose EYLEA contributed approximately $4.77 billion in US sales during 2024. EYLEA HD, the 8mg formulation approved in 2023, generated approximately $1.2 billion in US sales during 2024. The higher-dose version supports longer treatment intervals for eligible patients, potentially reducing injection frequency compared with standard anti-VEGF dosing schedules. The report, added to ResearchAndMarkets.com's catalogue, covers seven major pharmaceutical markets including the United States, Germany, France, Italy, Spain, the United Kingdom and Japan, with historical analysis from 2020 and forecasts through 2034.